Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis
| Autor: | Jenny H. Kang, Zoe Bider-Canfield, T. Craig Cheetham, Evo Alemao, Sean E. Connolly, Antony T. Lin, Jaejin An |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male musculoskeletal diseases Oncology medicine.medical_specialty Pharmaceutical Science Pharmacy Anti-Citrullinated Protein Antibodies Drug Costs Arthritis Rheumatoid Cohort Studies 03 medical and health sciences 0302 clinical medicine Cost of Illness Internal medicine medicine Humans 030212 general & internal medicine skin and connective tissue diseases Aged Retrospective Studies business.industry 030503 health policy & services Health Policy Health Care Costs Middle Aged Patient Acceptance of Health Care medicine.disease United States Antirheumatic Agents Potential biomarkers Rheumatoid arthritis Economic evaluation Female Treatment decision making 0305 other medical science business Biomarkers Follow-Up Studies |
| Zdroj: | Journal of Managed Care & Specialty Pharmacy. 25:469-477 |
| ISSN: | 2376-1032 2376-0540 |
| Popis: | Anticyclic citrullinated peptide (anti-CCP) positivity may be a strong predictor of joint erosion and a potential biomarker for guiding treatment decisions for rheumatoid arthritis (RA). However, limited studies are currently available on the effect of anti-CCP positivity on health care utilization and/or medical costs of RA patients.To investigate short-term and long-term direct health care expenditures associated with anti-CCP positivity in newly diagnosed RA patients.A retrospective cohort study was conducted in adult RA patients within a U.S. integrated health care delivery system (January 1, 2007-June 30, 2015). Patients were required to have 2 RA diagnoses and treatment with a conventional or biologic disease-modifying antirheumatic drug (DMARD) within 12 months. The first RA diagnosis date was labeled as the index date, and patients were followed until they left the health plan, died, or reached the end of the study period. Patient demographics, anti-CCP results, comorbid conditions, and health care resource utilization during baseline (12 months before the index date) and follow-up periods were collected. Nationally recognized direct medical costs were assigned to health care utilization to calculate health care costs in 2015 U.S. dollars. The baseline differences between anti-CCP positivity and negativity and differences in censoring during follow-up were addressed using propensity scores. The mean differences in costs were estimated using recycled prediction methods.2,448 newly diagnosed RA patients were identified and followed for a median of 3.7 years (range = 1-8 years). At baseline, 65.8% of patients were anti-CCP positive. Anti-CCP-positive patients had fewer comorbid conditions at baseline. During the first 12 months of follow-up, median (interquartile range) total health care expenditures for anti-CCP-positive and anti-CCP-negative patients were $6,200 ($3,563-$13,260) and $7,022 ($3,885-$12,995), respectively. After adjusting for baseline differences, total incremental mean cost associated with anti-CCP positivity during the first 12 months was estimated to be $2,163 per patient (P = 0.001). The annual incremental costs in anti-CCP-positive patients became progressively larger over time, from $2,163 during the first year to $5,062 during the fourth year. Anti-CCP positivity was associated with higher prescription, laboratory testing, and rheumatologist utilization. A higher percentage of anti-CCP-positive patients received 1 or more biologic DMARDs (11.6% for anti-CCP-positive vs. 5.7% for anti-CCP negative; P0.001) compared with anti-CCP-negative patients during the 12-month follow-up, which resulted in $2,499 in incremental prescription costs (P0.001). Total additional burden associated with anti-CCP positivity during the first 4 years was estimated to be $14,089 per patient.In newly diagnosed RA patients, higher economic burden associated with anti-CCP positivity was mainly driven by prescription costs.This research and manuscript were funded by Bristol-Myers Squibb (BMS). Alemao and Connolly are employees and shareholders of BMS and participated in the design of the study, interpretation of the data, review/revision of the manuscript, and approval of the final version of the manuscript. An and Cheetham received a grant from BMS for this research. At the time of this study, An was employed by Western University of Health Sciences, and Cheetham was employed by Kaiser Permanente Southern California. Bider-Canfield, Kang, and Lin have nothing to disclose. Some study results were presented as a poster at the American College of Rheumatology Annual Meeting; November 5, 2017; San Diego, CA, and at the International Society for Pharmacoeconomics and Outcomes Research Meeting; May 19, 2018; Baltimore, MD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|